Parashar Biswas | Global engineering leadershipPharmaceutical
↓Pharmaceutical
Engineering &
Capital Projects.
Three decades of experience connecting global engineering delivery, manufacturing operations, CQV, technology transfer and regulatory readiness.
From concept development to commercial manufacturing.
CAPITAL PROJECTSMANUFACTURING OPERATIONSCQV & TECHNOLOGY TRANSFERGLOBAL DELIVERY
Engineering leadership.Global delivery.
01 / Executive profile
Senior Pharmaceutical Engineering & Capital Projects Leader.
Parashar Biswas brings three decades of experience across pharmaceutical manufacturing, biotechnology, sterile injectables, oral solid dosage, validation science, technology transfer, combination products and commercial manufacturing.
Currently Director at Viatris, his work connects complex pharmaceutical programs across India, Ireland and international markets. He combines engineering depth with executive education in management, finance, international business and pharmaceutical validation technology.
Read the executive profile02 / Education & executive developmentEngineering knowledge.
All education & credentials Engineering knowledge.
Strategic perspective.
ISB-NUS GAMP
Global Advanced Management Programme, Indian School of Business in collaboration with NUS Business School, Singapore. Alumni ISB.
Pharmaceutical Validation Technology
Postgraduate MS qualification at Technological University Dublin, Ireland. Alumni TU Dublin.
Finance & industry certification
Financial Management executive education at IIM Bangalore, 2016; Certified Pharmaceutical Industry Professional (CPIP), ISPE USA, 2014.
03 / Professional journeyGlobal programs.
Complete career chronology Global programs.
Lifecycle leadership.
A career beginning in 1991, with engineering and project leadership roles across Viatris, CAI, Ranbaxy, Sandoz and earlier organizations.
01
022014-2015
Project Manager / Commissioning & Qualification
Commissioning Agents Inc. (CAI) - Singapore
View experience
03Illustrative pharmaceutical engineering imagery; not photographs of the named companies or projects.
04 / Current major programs | 2023-2027Advanced manufacturing.
India | Approved CAPEX: $110 Mn India / Ireland | CAPEX approved to date: $150 Mn
Advanced manufacturing.
Complex program delivery.
The October 2026 CV identifies two major programs connecting facility engineering, CQV, manufacturing technologies and commercialization.
Greenfield aseptic manufacturing facility
Project management for an approximately 10,000 m² greenfield aseptic facility. The scope includes microsphere and liposome products, with liquid and dry-powder manufacturing capability.
The program brings together facility design, engineering, execution and CQV.
Explore the programGLP-1 autoinjector device project
Project Head for medical-device and combination-product manufacturing activities associated with the Wegovy program.
Scope covers exhibit-batch manufacturing, protocols, qualification, commercialization and regulatory submission activities, alongside high-speed device assembly, labelling and packaging.
Explore combination-product experience05 / Capital-project leadershipFrom strategic investment
Explore project delivery From strategic investment
to commercial manufacturing.
Parashar's project leadership spans the full pharmaceutical facility lifecycle. His work brings together concept development, engineering, procurement, construction, commissioning and qualification with manufacturing needs, technology transfer and commercialization. This connects the technical requirements of a facility with the operational and business context in which it will be used.
Working in global matrix organizations, he coordinates manufacturing, engineering, quality, regulatory, procurement, technical operations and external partners. The CV emphasizes governance, risk management, project planning, stakeholder alignment and delivery performance, alongside collaboration with EPCM organizations, consultants, equipment suppliers and CMOs.
Capital portfolio perspective
Strategic capital planning, enterprise portfolio management, PMO and project governance are central leadership capabilities. Responsibilities include project proposals, qualification of projects from concept stage, staff utilization and coordination of project assignments.
Greenfield and brownfield delivery
Experience includes facility design, engineering, procurement, construction support and risk resolution. Projects range from finished-formulation facilities to complex sterile injectables, oncology containment and aseptic manufacturing.
A risk-based engineering approach
The CV identifies ASTM E2500, ICH Q9, impact assessments, traceability and change-control principles. Additional capabilities include process validation, cGMP documentation and readiness for USFDA, EU GMP and MHRA environments.
06 / Selected delivery experienceSpecialist technologies.
Specialist technologies.
Practical project leadership.
$50 Mn complex sterile injectable formulation facility, India | 2015-2017Sterile oncology facility with OEB 4-5 containment and closed-RABS concepts | 2017-2020India-to-Indonesia sterile injectable technology transfer | Completed Q2 2022South Africa brownfield ARV / Prednisone facility | Approx. $29 Mn investmentNigeria greenfield oral solid dosage facility | Approx. $18 Mn investmentSandoz tablet and capsule facility, India | Approx. $29 Mn investment
07 / Global deliveryAsia. Europe. Africa.
Asia. Europe. Africa.
Connected by collaboration.
The CV describes multinational and cross-functional team leadership across Asia, Europe and Africa. International experience includes India, Ireland, Singapore, South Africa, Nigeria and Indonesia / Southeast Asia.
Parashar's experience brings together international project teams, engineering consultants, EPCM organizations, CMOs, equipment suppliers and regulatory stakeholders. Cross-cultural collaboration and executive stakeholder management support delivery in complex global organizations.
Leadership background- India
- Ireland
- Singapore
- South Africa
- Nigeria
- Indonesia / Southeast Asia
08 / Research & transformationSustainable engineering.
Sustainable engineering.
Digital possibilities.
Executive education and technical experience are complemented by a growing focus on AI-enabled pharmaceutical manufacturing, digital transformation, Digital Twins, Industry 4.0 and sustainable engineering.
Research & insightsESG maturity in manufacturing
The CV lists a July 2026 published research paper: “A Proposed ESG Maturity Assessment Model (EMAM) for Pharmaceutical Manufacturing: Framework, Methodology, Validation Approach”. A publication overview is available in Research & Insights.
Digital manufacturing & AI
Areas of interest include smart manufacturing, data-driven quality, AI-enabled validation concepts and digital manufacturing. These are presented as developing interests and capabilities alongside the established engineering portfolio.
Professional community
Affiliations listed in the CV include ISPE since 2006, PDA and PMI since 2010, ASQ since 2025 and ResearchGate since 2026.
Education & affiliations09 / Frequently asked questionsExperience.
Experience.
Education. Perspective.
Answers based on the professional CV dated 1 October 2026.
Contact ParasharWhat is Parashar Biswas's current professional role?
The CV dated 1 October 2026 lists Parashar Biswas as Director, Engineering & Capital Projects at Viatris, with experience supporting pharmaceutical programs across India, Ireland and international markets.
What does his pharmaceutical project experience cover?
His experience spans concept development, design and engineering, procurement, construction, commissioning, qualification, technology transfer, regulatory readiness and commercialization. Manufacturing areas include sterile injectables, oncology, oral solid dosage, biotechnology and combination products.
Which major programs are listed for 2023-2027?
The CV describes an approximately 10,000 square metre greenfield aseptic manufacturing facility in India with $110 million approved CAPEX, and a GLP-1 autoinjector device project involving India and Ireland with $150 million CAPEX approved to date. These are program budgets, not statements of completed expenditure.
Was the India-to-Indonesia technology transfer completed?
Yes. The CV records completion in Q2 2022. The project included facility upgrades, equipment procurement, commissioning and qualification at a third-party CMO facility in Indonesia.
What education and professional certification are listed?
Education includes ISB-NUS GAMP in June 2026, Pharmaceutical Validation Technology at TU Dublin in 2020, an MBA in International Business in 2008, Mechanical Engineering graduation in 1990, IIM Bangalore Financial Management executive education in 2016 and ISPE USA CPIP certification in 2014.
What research is included in the CV?
The CV lists a July 2026 publication titled A Proposed ESG Maturity Assessment Model (EMAM) for Pharmaceutical Manufacturing: Framework, Methodology, Validation Approach. Research interests include ESG, sustainable engineering, digital manufacturing, AI, validation science and innovation management.
How can I contact Parashar Biswas?
Parashar is based in Bengaluru, India. Call +91 9878610760 or email parashar993@gmail.com. His LinkedIn profile is linked on the Contact page.